Equities

Adalta Ltd

1AD:ASX

Adalta Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.026
  • Today's Change0.001 / 4.00%
  • Shares traded20.00k
  • 1 Year change+13.04%
  • Beta0.9394
Data delayed at least 20 minutes, as of Jun 14 2024 07:10 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

AdAlta Limited is an Australia-based clinical-stage biotechnology company. The Company uses its i-body platform to discover and develop protein therapeutics addressing drug targets that are challenging for other technologies. The Company's first-in-class lead asset, AD-214, is being developed for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases, for which current therapies are sub-optimal. AD-214 is an Fc-Fusion protein that contains two AD-114 i-body molecules at the front end, that bind with high affinity to the human target, CXCR4. It is also engaged in developing i-body enabled Chimeric antigen receptor T cell (CAR-T) cells. It co-develops i-bodies as diagnostic imaging agents (i-PET imaging) against Granzyme B, a biomarker of response to immuno-oncology drugs.

  • Revenue in AUD (TTM)3.56m
  • Net income in AUD-5.04m
  • Incorporated2006
  • Employees--
  • Location
    Adalta LtdUnit 15 / 2 Park Drive, BundooraMELBOURNE 3083AustraliaAUS
  • Phone+61 39479-5159
  • Fax+61 39479-3666
  • Websitehttps://adalta.com.au/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Bioxyne Ltd8.65m-14.17m12.28m16.00--3.94--1.42-0.0074-0.00740.00440.00151.836.1210.50---302.23-22.07-418.10-28.5038.3045.13-165.04-39.691.50--0.00--1,013.0520.97-292.69---19.86--
Tissue Repair Ltd457.52k-3.28m12.70m----0.7373--27.75-0.0542-0.05420.00760.28480.0209--7.95---14.96---15.46--98.19---716.30--25.84--0.00------38.95------
Firebrick Pharma Ltd0.00-4.57m13.09m----7.51-----0.0266-0.02660.000.00890.00-------120.70---136.04----------4.37--0.00---79.85---79.18------
Argent BioPharma Ltd1.32m-17.02m13.58m----8.07--10.26-3.32-3.320.10030.03720.08130.70781.58---105.32-111.29-345.98-171.0521.8732.52-1,295.20-632.420.6561-24.850.4104---28.4147.31-2.34---16.20--
Radiopharm Theranostics Ltd0.00-46.82m13.81m----0.4601-----0.1343-0.13430.000.06520.00-------63.11---77.85-------------7.480.00-------13.78------
Chimeric Therapeutics Ltd0.00-11.31m14.67m----0.8901-----0.027-0.0270.000.01910.00-------45.96---69.36-------------10.010.1596-------60.40------
Medlab Clinical Ltd366.64k-3.94m15.07m14.00------41.11-1.73-1.730.1606-0.30680.1069--5.82---103.72-55.07-240.52-69.7584.7752.86-970.74-335.43---342.19-----28.90-29.8318.55---30.00--
Calmer Co International Ltd2.46m-4.50m15.09m--------6.13-0.0083-0.00830.0039-0.00050.6551.349.62---119.81-139.15-231.33-198.5536.0330.26-182.94-388.810.482-9.361.22---13.00239.4311.40------
Adalta Ltd3.56m-5.04m15.49m----5.65--4.35-0.0129-0.01290.00920.00460.5491--4.72---77.76-67.77-195.09-103.16-----141.60-160.72---57.860.4533--28.1811.1719.96---7.47--
Lumos Diagnostics Holdings Ltd12.38m-13.29m15.88m----1.14--1.28-0.0357-0.03570.03520.02890.34182.246.37---36.70-40.15-55.14-56.6759.7345.97-107.38-162.900.479-6.250.4803---9.4239.2980.38---38.50--
Rhythm Biosciences Ltd157.67k-8.63m16.41m----11.99--104.06-0.0386-0.03860.00070.00550.0263--1.81---144.00-106.11-169.71-125.51-1,899.74-1,210.71-5,473.20-6,642.262.04--0.0304--814.1828.776.55---20.43--
Patrys Ltd1.70m-5.12m16.46m15.00--3.28--9.71-0.0025-0.00250.00080.00240.1978--0.5828---59.77-43.96-68.99-47.06-----302.26-230.44----0.00---14.4540.52-4.15------
Oncosil Medical Ltd355.30k-11.71m16.66m2.00--2.56--46.89-0.0081-0.00810.00020.0020.0506--7.88---166.55-57.65-234.81-64.83-426.96---3,295.08-473.02---68.930.0256---59.92-37.72-5.74--40.13--
Auscann Group Holdings Ltd2.05m-9.44m17.75m27.00------8.66-0.0213-0.02170.00430.01620.1674--5.35---77.15-39.85-78.72-40.73100.59---460.74-925.91---23.160.00--13.8851.3757.10------
Amplia Therapeutics Ltd4.44m-4.50m18.20m1.00--1.17--4.10-0.0226-0.02260.02220.05720.2647--2.05---26.86-25.13-32.90-27.42-----101.48-206.74----0.122--286.42144.8127.86---6.91--
Algorae Pharmaceuticals Ltd84.10k-2.25m18.56m----5.12--220.71-0.0015-0.00150.000060.00220.0245--1.79---65.51-46.12-70.91-53.52-----2,678.04-591.05---136.750.00--1,132.26-44.06-7.68------
Data as of Jun 14 2024. Currency figures normalised to Adalta Ltd's reporting currency: Australian Dollar AUD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.